Research And Development
Health
Medical
OPKO Health
$2.589876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.05 (1.98%) Today
+$0.01 (0.39%) After Hours
Why Robinhood?
You can buy or sell OPKO Health and other stocks, options, ETFs, and crypto commission-free!
About
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. Read More The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Employees
5,690
Headquarters
Miami, Florida
Founded
1991
Market Cap
1.48B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
5.75M
High Today
$2.57
Low Today
$2.50
Open Price
$2.54
Volume
1.20M
52 Week High
$6.40
52 Week Low
$2.34
Collections
Research And Development
Health
Medical
Healthcare
Pharmaceutical
Biotechnology
Technology
US
News
Seeking AlphaMar 21
OPKO up 7% premarket on positive OPK88003 data
OPKO Health (NASDAQ:OPK) is up 7% premarket on increased volume on the heels of positive topline results from a Phase 2 dose-escalation study evaluating OPK88003, a weekly injectable oxyntomodulin compound with dual glucagon-like-peptide 1 (GLP-1) and glucagon agonist activity, in adult type 2 diabetics with inadequate blood sugar control with metformin and/or diet and exercise.
Yahoo FinanceMar 21
OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial
OPKO Health’s Oxyntomodulin, OPK88003, Shows Significant Reduction in HbA1c and Body Weight in Patients with Type 2 Diabetes MIAMI, March 21, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) today announced positive topline results from a Phase 2 dose escalation trial of OPK88003 to treat type 2 diabetes and obesity. OPK88003 is a once-weekly injectable oxyntomodulin compound with glucagon-like-peptide 1 (GLP-1) and glucagon dual agonist activity. Based on data from a previous 420 patient Phase 2 study, an...
Yahoo FinanceMar 4
OPKO Health (OPK) Reports Loss in Q4, Misses on Revenues
OPKO Health, Inc. OPK incurred adjusted loss of 8 cents per share in fourth-quarter 2018, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The company had incurred a loss of 12 cents per share in the year-ago quarter. On a GAAP basis, the Zacks Rank #3 (Hold) company incurred a loss of 13 cents per share. Revenues totaled $221.9 million, which missed the Zacks Consensus Estimate of $242 million. However, on a year-over-year basis, the top line increased 37.8%. 2018 at a Glance Net revenu...
Price Paid on Robinhood
45% Lower
Right Now
52 Week Low
$2.34
Average Price Paid
$4.66
52 Week High
$6.40
Earnings
-$0.32
-$0.22
-$0.11
-$0.01
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, After Hours